Skip to main content

Breast Cancer

Ausgabe 5/2019

Inhalt (18 Artikel)

Open Access Original Article

Pharmacogenomic–pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer

Hiroshi Ishiguro, Shinji Ohno, Yutaka Yamamoto, Shintaro Takao, Nobuaki Sato, Tomomi Fujisawa, Takayuki Kadoya, Katsumasa Kuroi, Hiroko Bando, Yasufumi Teramura, Hiroji Iwata, Shiro Tanaka, Masakazu Toi

Original Article

Relationships among personality, coping, and concurrent health-related quality of life in women with breast cancer

Hui-Ling Lai, Chun-I. Chen, Chu-Yun Lu, Yu-Chun Yao, Chiung-Yu Huang

Open Access Original Article

The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan

Wakana Murakami, Mitsuhiro Tozaki, Seigo Nakamura, Yoshimi Ide, Mayuko Inuzuka, Yuko Hirota, Kouzou Murakami, Noritsugu Takahama, Yoshimitsu Ohgiya, Takehiko Gokan

Original Article

Impact of germinal center-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population

Haruru Kotani, Hidemi Ito, Kazuhiko Kuwahara, Kiyotaka Kuzushima, Hiroji Iwata, Nobuyuki Tsunoda, Masato Nagino, Keitaro Matsuo

Original Article

Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer

Kayo Fukui, Norio Masumoto, Noriyuki Shiroma, Akiko Kanou, Shinsuke Sasada, Akiko Emi, Takayuki Kadoya, Michiya Yokozaki, Koji Arihiro, Morihito Okada

Original Article

Breast cancer cell motility is promoted by 14-3-3γ

Emiko Hiraoka, Takahiro Mimae, Masaoki Ito, Takayuki Kadoya, Yoshihiro Miyata, Akihiko Ito, Morihito Okada

Correction

Correction to: Breast cancer cell motility is promoted by 14-3-3γ

Emiko Hiraoka, Takahiro Mimae, Masaoki Ito, Takayuki Kadoya, Yoshihiro Miyata, Akihiko Ito, Morihito Okada

Original Article

Lateral thoracoaxillar dermal-fat flap for breast conserving surgery: the changes of the indication and long-term results

Hiroshi Nakagomi, Masayuki Inoue, Haruka Nakada, Masato Ohmori, Yuko Nakayama, Kazushige Furuya, Hideki Watanabe, Kou Ikegame, Koichi Kobayashi

Original Article

C677T and A1298C methylenetetrahydrofolate reductase polymorphisms and breast cancer susceptibility among Latinos: a meta-analysis

Perla Meneses-Sanchez, Samantha C. Garcia-Hernandez, Leonardo M. Porchia, Ricardo Pérez-Fuentes, Enrique Torres-Rasgado, Alejandra Del Angel Soto, M. Elba Gonzalez-Mejia

Original Article

Sentinel node mapping and ductal carcinoma in situ

Samara E. Pollock, Jondavid Pollock, Scott Nestor, Rosemarie Hardin, David Ghaphery

Original Article

Oncologic outcomes and radiation safety of nipple-sparing mastectomy with intraoperative radiotherapy for breast cancer

Lingxiao Pan, Changsheng Ye, Lun Chen, Wei Tang, Xiaoshen Zhang, Jin Gao, Rui Wu, Xigang Ye, Weige Tan, Minghui Wan, Wenbo Zheng

Original Article

Predicting metastasis in clinically negative axillary lymph nodes with minimum apparent diffusion coefficient value in luminal A-like breast cancer

Fumi Kato, Kohsuke Kudo, Hiroko Yamashita, Motoi Baba, Ai Shimizu, Noriko Oyama-Manabe, Rumiko Kinoshita, Ruijiang Li, Hiroki Shirato

Open Access Original Article

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

Norikazu Masuda, Hirofumi Mukai, Kenichi Inoue, Yoshiaki Rai, Shinji Ohno, Yuko Mori, Satoshi Hashigaki, Yasuaki Muramatsu, Yoshiko Umeyama, Hiroji Iwata, Masakuzu Toi

Correction

Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

Norikazu Masuda, Hirofumi Mukai, Kenichi Inoue, Yoshiaki Rai, Shinji Ohno, Yuko Mori, Satoshi Hashigaki, Yasuaki Muramatsu, Yoshiko Umeyama, Hiroji Iwata, Masakazu Toi

Open Access Original Article

PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation

Xueqiang Gao, Xiangping Liu, Yangyong Lu, Yu Wang, Weihong Cao, Xiaoyi Liu, Haiyan Hu, Haibo Wang

Original Article

Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy

Anbok Lee, Sunmi Jo, Changhu Lee, Hyun-Hee Shin, Tae Hyun Kim, Ki Jung Ahn, Sung-Kwang Park, Heunglae Cho, Hye-Kyoung Yoon, Woo Gyeong Kim, Jiyoung Park, Yunseon Choi

Rapid Communication

Discrepancies of current recommendations in breast cancer follow-up: a systematic review

Anastasios Kyriazoglou, Flora Zagouri, Despina Fotiou, Constantinos Dimitrakakis, Spyros Marinopoulos, Roubini Zakopoulou, Maria Kaparelou, Anna Zygogianni, Meletios Athanasios Dimopoulos

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.